Data from preclinical studies of a newly developed antibody shows it to be more effective than monoclonal antibodies in clinical trials, while providing defense against a broader range of threats. As new ground is being broken in vaccine development and the prospects for several successful vaccines against SARS-CoV-2 look promising, the importance of finding a successful treatment for this coronavirus and those like it does not diminish. New in vivo and in vitro data from a novel therapeutic for SARS-CoV-2, currently in preclinical trials, have been released. The data show the therapeutic, an antibody labeled ADG2, to be as (or...
To view this content, please register now for access
Become a member of BioTechniques for FREE to receive:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!